Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | ||||||
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | ||||||
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | ||||||
| 6 | Public support. Subtract line 5 from line 4. | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | ||||||
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | ||||||
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | ||||||
| 11 | Total support. Add lines 7 through 10 | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | 9,978,694 | 8,575,801 | 7,525,300 | 6,446,971 | 7,826,511 | 40,353,277 |
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | 93,297,144 | 136,574,903 | 123,116,955 | 98,737,324 | 80,888,354 | 532,614,680 |
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | 103,275,838 | 145,150,704 | 130,642,255 | 105,184,295 | 88,714,865 | 572,967,957 |
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | 75,000 | 75,000 | ||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | 0 | |||||
| c | Add lines 7a and 7b.. | 75,000 | 75,000 | ||||
| 8 | Public support. (Subtract line 7c from line 6.) | 572,892,957 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | 103,275,838 | 145,150,704 | 130,642,255 | 105,184,295 | 88,714,865 | 572,967,957 |
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | 5,969,247 | 7,763,043 | 8,610,595 | 18,248,056 | 15,214,892 | 55,805,833 |
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | 5,969,247 | 7,763,043 | 8,610,595 | 18,248,056 | 15,214,892 | 55,805,833 |
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | 2,871,782 | 4,855,029 | 7,776,132 | 8,302,393 | 7,677,032 | 31,482,368 |
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | 248,859 | 255,345 | 251,085 | 755,289 | ||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | 112,365,726 | 158,024,121 | 147,280,067 | 131,734,744 | 111,606,789 | 661,011,447 |
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2021 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2021 |
(iii) Distributable Amount for 2021 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2021 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2021 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2021: | ||||
| a From 2016....... | ||||
| b From 2017....... | ||||
| c From 2018....... | ||||
| d From 2019....... | ||||
| e From 2020....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2021 distributable amount | ||||
|
i
Carryover from 2016 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2021 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2021 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2021, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2021. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2022. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2017..... | ||||
| b Excess from 2018..... | ||||
| c Excess from 2019..... | ||||
| d Excess from 2020..... | ||||
| e Excess from 2021..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| FORM 990, PART III, LINE 1 | ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, AND PROMOTION OF THE HIGHEST QUALITY, EQUITABLE PATIENT CARE. ASCO'S VISION IS A WORLD WHERE CANCER IS PREVENTED OR CURED, AND EVERY SURVIVOR IS HEALTHY. ASCO PROMOTES AND PROVIDES FOR: - LIFELONG LEARNING FOR ONCOLOGY PROFESSIONALS, - CANCER RESEARCH, - AN IMPROVED ENVIRONMENT FOR ONCOLOGY PRACTICE, - ACCESS TO QUALITY CANCER CARE, - A GLOBAL NETWORK OF ONCOLOGY EXPERTISE, AND - EDUCATED AND INFORMED PATIENTS WITH CANCER. |
| FORM 990, PART III, LINE 4A: | QUALITY OF CARE: ASCO, THROUGH COLLECTION OF ONCOLOGY PRACTICE CARE DELIVERY METRICS, DEVELOPS INSIGHTS TO IMPROVE THE QUALITY AND EQUITY OF ONCOLOGY CARE DELIVERY. ASCO ALSO PRODUCES EVIDENCE-BASED GUIDELINES, QUALITY MEASURES AND DEVELOPS STANDARDS FOR QUALITY ONCOLOGY CARE, AND PROVIDES TRAINING IN QUALITY CARE IMPROVEMENT. CANCERLINQ'S BIG-DATA PLATFORM DELIVERS VALUABLE INSIGHTS AND TOOLS TO PARTICIPATING PRACTICES AND DE-IDENTIFIED DATA FOR CANCER TREATMENT RESEARCH. THE CANCERLINQ DATABASE, WHICH INCLUDES INFORMATION FROM MILLIONS OF CANCER PATIENT CARE RECORDS, REFLECTS CANCER CARE IN ALL ITS REAL-WORLD VARIABILITY, ALLOWING CLINICIANS TO LEARN FROM THE EXPERIENCE OF EVERY PATIENT. QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI). A QUALITY SELF ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES: QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICE STAFF TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. QUALITY TRAINING PROGRAM. ASCO'S QUALITY TRAINING PROGRAM IS DESIGNED TO EDUCATE AND TRAIN PRACTICES THE TECHNIQUES OF CLINICAL CARE AND OPERATIONAL PERFORMANCE QUALITY IMPROVEMENT. |
| FORM 990, PART III, LINE 4B: | SCIENTIFIC AND MEDICAL EDUCATION: ASCO PROVIDES SCIENTIFIC AND EDUCATIONAL PROGRAMS AND CONTENT ON A BROAD RANGE OF ONCOLOGY-RELATED TOPICS IN A VARIETY OF FORMATS. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS AND PRESENTS MEETINGS ON THE LATEST CANCER RESEARCH AND EDUCATIONAL SESSIONS HIGHLIGHTING ADVANCES IN RESEARCH AND ONCOLOGY CARE. ASCO'S PROGRAMS ARE DESIGNED TO SERVE THE DIVERSE NEEDS OF ONCOLOGY PRACTITIONERS WORLDWIDE, ASSISTING THEM IN DELIVERING HIGH QUALITY CANCER CARE AND CONDUCTING CLINICAL RESEARCH THROUGH THE CONTINUUM OF THEIR CAREERS. PROGRAMS ADDRESS ONGOING RESEARCH AND THE MODERN- DAY PRACTICE OF ONCOLOGY FOR THE COMMUNITY OF MULTIDISCIPLINARY ONCOLOGY CARE PROVIDERS. ASCO ANNUAL MEETING IS THE WORLD'S PREMIER SCIENTIFIC AND EDUCATIONAL CLINICAL ONCOLOGY MEETING. ASCO ALSO SPONSORS OR CO-SPONSORS THEMATIC MEETINGS (FOCUSING ON SUBSPECIALTY AREAS), WHICH PROVIDE OPPORTUNITIES FOR FOCUSED EDUCATIONAL AND SCIENTIFIC SESSIONS ON SPECIFIC TYPES OF CANCERS. HIGHLIGHTS OF THE 2021 VIRTUAL ANNUAL MEETING INCLUDE OVER 5,000 SCIENTIFIC ABSTRACTS FOR NEARLY 33,000 ATTENDEES. THE GASTROINTESTINAL CANCERS AND THE GENITOURINARY CANCERS SYMPOSIA COVERED 751 AND 580 ABSTRACTS, RESPECTIVELY, FOR 4,100 AND 5,150 ATTENDEES. CONTENT IS MAINTAINED DIGITALLY AND MADE ACCESSIBLE. DUE TO THE COVID-19 PANDEMIC, ASCO'S MEETINGS WERE PRESENTED VIRTUALLY THROUGH JUNE, 2021. THESE MEETINGS ARE NOW PRESENTED IN BOTH A VIRTUAL AND IN-PERSON (HYBRID) FORMAT. THE HYBRID FORMAT HAS ENABLED PARTICIPATION FROM A LARGER AND MORE DIVERSE DOMESTIC AND INTERNATIONAL AUDIENCE. ASCO'S SCIENTIFIC AND EDUCATION PROGRAMS ALSO INCLUDE DIGITAL EDUCATION PROGRAMS, PROFESSIONAL DEVELOPMENT ACTIVITIES, AND LICENSING PROGRAMS THAT ALLOW ASCO TO BROADLY DELIVER ITS MATERIALS AND EDUCATION FOR THE ENTIRE SPECTRUM OF PROFESSIONALS WORKING IN ONCOLOGY CARE. IN 2021, ASCO HELD THE STATUS OF JOINT ACCREDITATION FROM THE ACCREDITATION COUNCIL FOR CONTINUING MEDICAL EDUCATION, ALLOWING ASCO TO PROVIDE CONTINUING EDUCATION CREDIT FOR PHYSICIANS, NURSES AND PHARMACISTS. |
| FORM 990, PART III, LINE 4C: | SCIENTIFIC PUBLICATIONS: ASCO PRODUCES A NUMBER OF PROFESSIONAL PUBLICATIONS AND GENERAL PUBLICATIONS FOCUSED ON CLINICAL ONCOLOGY. ASCO PUBLISHES HIGH-QUALITY, PEER-REVIEWED SCIENTIFIC PAPERS IN ITS JOURNALS: - JOURNAL OF CLINICAL ONCOLOGY (JCO) IS A HIGHLY REGARDED JOURNAL PUBLISHING SCIENTIFIC MANUSCRIPTS AND ARTICLES ON SIGNIFICANT CLINICAL ONCOLOGY RESEARCH IN PRINT AND ELECTRONIC FORMATS. JCO IS MAILED THREE A TIMES A MONTH TO OVER 17,000 ASCO MEMBERS. OVER 3,000 GLOBAL INSTITUTIONS SUBSCRIBE TO THE PUBLICATION, PRINT AND ONLINE. - JCO ONCOLOGY PRACTICE (JCO OP) PUBLISHES ORIGINAL RESEARCH AND INSIGHTS TO KEEP ONCOLOGY PRACTICES CURRENT ON CHANGES AND CHALLENGES INHERENT IN DELIVERING EQUITABLE, HIGH-QUALITY ONCOLOGY CARE WITH AN EVOLVING VALUE-BASED LENS. ALL CONTENT DEALING WITH UNDERSTANDING THE PROVISION OF CARE - THE MECHANICS OF PRACTICE, CARE DELIVERY, QUALITY IMPROVEMENT, VALUE, AND EQUITY - IS THE PURVIEW OF JCO OP. JCO OP ALSO ADDRESSES AN EXPRESSED NEED BY PRACTICING PHYSICIANS TO HAVE COMPRESSED, EXPERT OPINION ADDRESSING COMMON CLINICAL PROBLEMS WITH PERSPECTIVES BY DISEASE EXPERTS. JCO OP MAILS MONTHLY TO APPROXIMATELY 24,000 ASCO MEMBERS AS WELL AS AFFILIATED MEDICAL PROFESSIONALS. - JCO GLOBAL ONCOLOGY (JCO GO) IS AN ONLINE-ONLY, OPEN ACCESS JOURNAL FOCUSING ON CANCER CARE, RESEARCH, AND CARE DELIVERY ISSUES UNIQUE TO COUNTRIES AND SETTINGS WITH LIMITED HEALTHCARE RESOURCES. - JCO CLINICAL CANCER INFORMATICS (JCO CCI) IS AN ONLINE-ONLY INTERDISCIPLINARY JOURNAL THAT PUBLISHES CLINICALLY RELEVANT RESEARCH BASED ON BIOMEDICAL INFORMATICS METHODS AND PROCESSES APPLIED TO CANCER-RELATED DATA, INFORMATION, AND IMAGES. - JCO PRECISION ONCOLOGY (JCO PO) IS AN ONLINE-ONLY JOURNAL PUBLISHING ORIGINAL RESEARCH, REPORTS, OPINIONS, AND REVIEWS THAT ADVANCE THE SCIENCE AND PRACTICE OF PRECISION ONCOLOGY AND DEFINES GENOMICS-DRIVEN CLINICAL CARE OF PATIENTS WITH CANCER. ASCO DAILY NEWS IS THE OFFICIAL CONFERENCE REPORT OF ASCO, WHICH PROVIDES SCIENTIFIC AND EDUCATIONAL SUMMARIES FROM ONCOLOGY CONFERENCES. IT IS MAILED TO OVER 10,000 ASCO MEETING ATTENDEES FOR THE ASCO ANNUAL MEETING AND THEMATIC MEETINGS. THE ONLINE VERSION PUBLISHES CONTENT YEAR-ROUND. ASCO ALSO PROVIDES CONTENT AND DISTRIBUTION LISTS FOR TRADE PUBLICATIONS. WHILE NOT OWNED OR PUBLISHED BY ASCO, THE PUBLICATIONS COVER NEWS AND INFORMATION OF INTEREST TO THE PROFESSIONAL ONCOLOGY COMMUNITY. |
| FORM 990, PART VI, SECTION A, LINE 1A | AS OF DECEMBER 31, 2021, THE BOARD OF DIRECTORS OF ASCO INCLUDED 19 MEMBERS WITH THE RIGHT TO VOTE ON ALL MATTERS THAT COME BEFORE THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDED ONE EX-OFFICIO DIRECTOR WITHOUT THE RIGHT TO VOTE, WHO WAS THE CHIEF EXECUTIVE OFFICER OF ASCO (CEO). DURING THE REPORTING YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO ACT ON ITS BEHALF TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. PURSUANT TO THE BYLAWS, THE VOTING MEMBERS OF THE EXECUTIVE COMMITTEE ARE THE PRESIDENT, THE PRESIDENT-ELECT, THE CHAIR, THE PAST PRESIDENT, THE TREASURER, THE TREASURER-ELECT, AND THOSE DIRECTORS SERVING THE FINAL YEAR OF THEIR PRESENT TERMS. THE CEO IS A NON-VOTING MEMBER OF THE EXECUTIVE COMMITTEE. ALL EXECUTIVE COMMITTEE MEMBERS ARE MEMBERS OF ASCO'S BOARD OF DIRECTORS. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY ASCO'S BYLAWS, WHICH PROVIDE THAT, EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT MAJOR DECISIONS BETWEEN BOARD MEETINGS, AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED MEETING OF THE BOARD OF DIRECTORS. ALL ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO THE BOARD OF DIRECTORS AT THE NEXT MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH ASCO'S BYLAWS. |
| FORM 990, PART VI, SECTION A, LINE 2 | DR. LORI J. PIERCE, FASTRO, FASCO, SERVED AS PRESIDENT AND CHAIR OF ASCO AND AS A MEMBER OF THE ASCO BOARD OF DIRECTORS DURING 2021. SHE ALSO SERVES AS A PROFESSOR OF THE DEPARTMENT OF RADIATION ONCOLOGY AT THE UNIVERSITY OF MICHIGAN, AND AS VICE PROVOST FOR ACADEMIC AND FACULTY AFFAIRS. DR. RESHMA JAGSI, FASTRO, FASCO, SERVED AS A MEMBER OF THE ASCO BOARD OF DIRECTORS DURING 2021. SHE ALSO SERVES AS DEPUTY CHAIR OF RADIATION ONCOLOGY AT THE UNIVERSITY OF MICHIGAN. DR. CLIFFORD HUDIS, LINDA JENSEN, AND MELISSA TAI WERE ALL EMPLOYED BY THE ASSOCIATION'S AFFILIATE, THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (THE SOCIETY), A SECTION 501(C)(3) PUBLIC CHARITY. DR. HUDIS IS THE CHIEF EXECUTIVE OFFICER OF THE SOCIETY AND MS. JENSEN IS THE CHIEF FINANCIAL OFFICER AND EXECUTIVE VICE PRESIDENT OF THE SOCIETY. DR. MONICA BERTAGNOLLI, DR. HOWARD BURRIS, III, DR. ERIC SMALL, DR. A. WILLIAM BLACKSTOCK, DR. LEE ELLIS, DR. LAURIE GASPAR, DR. RESHMA JAGSI, DR. MICHAEL KOSTY, DR. ELIZABETH MITTENDORF, DR. TONY MOK, DR. LORI PIERCE, DR. EVERETT VOKES, DR. TRACEY WEISBERG, AND DR. ERIC WINER ALL SERVED AS VOTING MEMBERS OF THE SOCIETY'S BOARD OF DIRECTORS DURING THE TAX YEAR. IN ADDITION, DURING THE TAX YEAR, DR. BERTAGNOLLI SERVED AS PAST PRESIDENT OF THE SOCIETY, DR. BURRIS SERVED AS CHAIR OF THE BOARD AND PAST PRESIDENT OF THE SOCIETY, DR. PIERCE SERVED AS PRESIDENT AND CHAIR OF THE BOARD OF THE SOCIETY, DR. VOKES SERVED AS PRESIDENT-ELECT AND PRESIDENT OF THE SOCIETY, DR. WINER SERVED AS PRESIDENT-ELECT OF THE SOCIETY, DR. GASPAR SERVED AS TREASURER OF THE SOCIETY, AND DR. MITTENDORF SERVED AS TREASURER-ELECT OF THE SOCIETY. |
| FORM 990, PART VI, SECTION A, LINE 4 | THE ASCO MEMBERSHIP APPROVED AMENDMENTS TO ASCO'S CERTIFICATE OF INCORPORATION AND BYLAWS THAT BECAME EFFECTIVE IN 2021. THE CERTIFICATE OF INCORPORATION WAS AMENDED TO PERMIT THE VOTING MEMBERS TO TAKE ACTION BY WRITTEN CONSENT IF (1) NO FEWER THAN 100 MEMBERS ELIGIBLE TO VOTE CONSENT TO SUCH ACTION IN WRITING OR ELECTRONICALLY, AND (2) SUCH ACTION IS APPROVED BY THE PROPORTION OF VOTES CAST BY MEMBERS ELIGIBLE TO VOTE AS WOULD BE REQUIRED TO APPROVE SUCH ACTION IF THE VOTES WERE CAST AT A MEETING OF THE MEMBERS. THE SIGNIFICANT AMENDMENTS TO THE BYLAWS INCLUDE THE FOLLOWING: ENHANCED BENEFITS FOR ALL MEMBERS WITH DOCTORAL-LEVEL DEGREES. PREVIOUSLY, THE BYLAWS MADE REFERENCE TO SPECIFIC CLASSES OF MEMBERS, SPECIFYING THAT "FULL MEMBERS" WERE PHYSICIANS ANDSOMEDOCTORAL LEVEL PROVIDERS, AND"OTHER MEMBERS" WERE MEMBER CLASSES AS DEFINED IN THE POLICY ADOPTED BY THE ASCO AND THE ASSOCIATION BOARDS OF DIRECTORS. UNDER THE PREVIOUS BYLAWS AND THE ASCO MEMBERSHIP POLICY, FULL MEMBERS AND SOME OF THE CATEGORIES OF OTHER MEMBERS HAD VOTING RIGHTS AND WERE ELIGIBLE TO SERVE ON THE ASCO BOARD OF DIRECTORS, ON THE ASCO NOMINATING COMMITTEE, OR AS ASCO ELECTED OFFICERS. TOGETHER, THOSE CATEGORIES REPRESENTED APPROXIMATELY 57% OF THE TOTAL ASCO MEMBERSHIP. THE AMENDMENTS REPLACED THE EXISTING CONCEPT OF "FULL MEMBERS AND "OTHER MEMBERS" WITH THE CONCEPT OF "MEMBERS AND "VOTING MEMBERS". UNDER THE AMENDED BYLAWS, "MEMBERS" REFERS TO ALL ASCO MEMBERS. "VOTING MEMBERS" REFERS TO THOSE MEMBERS WHO HAVE VOTING RIGHTS, AND ARE ELIGIBLE TO SERVE ON THE ASCO BOARD OF DIRECTORS, ON THE ASCO NOMINATING COMMITTEE, OR AS ASCO ELECTED OFFICERS. THE AMENDMENTS ALSO EXPANDED THE NUMBER OF ASCO MEMBERS WHO HAD THESE RIGHTS ANY ONCOLOGY MEDICAL PROFESSIONAL WITH A DOCTORAL-LEVEL DEGREE MAY BE A VOTING MEMBER. THE CHANGES WERE PROJECTED TO PERMIT APPROXIMATELY 83% OF TOTAL ASCO MEMBERSHIP TO HAVE VOTING RIGHTS AND BE ELIGIBLE TO SERVE ON THE BOARD OF DIRECTORS, ON THE NOMINATING COMMITTEE, OR AS AN ELECTED OFFICER. EXPANDED DIVERSITY ON THE BOARD OF DIRECTORS. PREVIOUSLY, THE BYLAWS REQUIRED THAT ALL MEMBERS OF THE BOARD OF DIRECTORS BE ONCOLOGISTS, WHO HAD TO BE PHYSICIANS. THE AMENDMENTS TO THE BYLAWS PERMIT THOSE BOARD MEMBERS WHO SIT IN "UNDESIGNATED" BOARD SEATS TO BE ANY ONCOLOGY PROFESSIONAL WITH A DOCTORAL- LEVEL DEGREE (NOT LIMITED TO PHYSICIANS). UNCONTESTED PRESIDENTIAL ELECTION. PREVIOUSLY, THE ASCO NOMINATING COMMITTEE SELECTED TWO NOMINEES EACH YEAR FOR PRESIDENT-ELECT THAT WERE THEN PRESENTED TO THE ASCO MEMBERSHIP FOR VOTE. UNDER THE APPROVED AMENDMENTS, EACH YEAR THE NOMINATING COMMITTEE WILL SELECT TWO CANDIDATES FOR THE ROLE OF PRESIDENT-ELECT, WHO ARE SUBMITTED TO THE ASCO BOARD OF DIRECTORS, WHICH THEN SELECTS THE BEST CANDIDATE FROM THE TWO CHOICES. THAT CANDIDATE IS PRESENTED TO THE ASCO MEMBERS FOR ELECTION THE ASCO VOTING MEMBERS MAY VOTE FOR THAT CANDIDATE, WRITE IN AN ALTERNATE CANDIDATE, OR ABSTAIN FROM VOTING. THIS CHANGE WAS INTENDED TO PERMIT THE NOMINATING COMMITTEE TO BETTER SUPPORT DIVERSITY IN THE ROLE OF PRESIDENT-ELECT FROM YEAR TO YEAR, WITH THE EXPECTATION THAT OVER THE LONG TERM, THE ASCO PRESIDENCY WILL REFLECT THE DIVERSITY OF THE MEMBERSHIP IN EVERY WAY: SPECIALTY, PROFESSIONAL SETTING, DEMOGRAPHICS, ANDOTHER CHARACTERISTICS. CONTINUITY IN THE ROLE OF TREASURER. PREVIOUSLY, THE ROLE OF TREASURER WAS TREATED AS A UNIQUE SEAT ON THE BOARD OF DIRECTORS, WITH ASCO MEMBERS VOTING FOR A CANDIDATE TO SERVE AS TREASURER EVERY FOUR YEARS. UNDER THE AMENDED BYLAWS, THE TREASURER-ELECT WILL BE ELECTED EACH YEAR FROM AMONG THE SERVING BOARD MEMBERS BY THE BOARD OF DIRECTORS. THE TREASURER-ELECT WILL SERVE A ONE-YEAR TERM, AND THEN SERVE A ONE-YEAR TERM AS TREASURER. THIS CHANGE WAS INTENDED TO ENSURE THAT THE ASCO TREASURER WOULD ALREADY HAVE EXPERIENCE WITH SOCIETY OPERATIONS FROM THEIR SERVICE ON THE BOARD AND AS TREASURER-ELECT BEFORE SERVING AS TREASURER. COMPOSITION OF NOMINATING COMMITTEE. PREVIOUSLY, THE NOMINATING COMMITTEE WAS COMPOSED OF THE ASCO PRESIDENT, CHAIR, AND THOSE OTHER NOMINATING COMMITTEE MEMBERS THAT WERE ELECTED BY THE ASCO MEMBERS. UNDER THE AMENDED BYLAWS, THE ASCO PRESIDENT-ELECT AND PAST PRESIDENT HAVE BEEN ADDED TO THE NOMINATING COMMITTEE. APPROVAL OF BYLAWS AMENDMENTS. PREVIOUSLY, PROPOSED AMENDMENTS HAD TO BE APPROVED BY A TWO-THIRDS VOTE OF THE ASCO MEMBERS ELIGIBLE TO VOTE TO BECOME EFFECTIVE. UNDER THE AMENDED BYLAWS, PROPOSED AMENDMENTS TO THE BYLAWS MUST BE APPROVED BY THE VOTE OF A MAJORITY OF THE VOTES CAST BY VOTING-ELIGIBLE MEMBERS TO BECOME EFFECTIVE. |
| FORM 990, PART VI, SECTION A, LINE 6 | VOTING MEMBERS. ALL ASCO MEMBERS MUST BE ONCOLOGY MEDICAL PROFESSIONALS, DEFINED AS INDIVIDUALS WHO MEET ANY OF THE FOLLOWING QUALIFICATIONS: (1) INDIVIDUALS WHOSE PROFESSIONAL CREDENTIALS AND ACTIVITIES INVOLVE CANCER PATIENT CARE AND/OR RESEARCH, EDUCATION, OR ADVOCACY IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER; (2) INDIVIDUALS WHO ARE RETIRED FROM PROFESSIONAL ACTIVITIES, BUT WHOSE PROFESSIONAL ACTIVITIES PRIOR TO RETIREMENT INCLUDED THOSE SET FORTH ABOVE; (3) INDIVIDUALS WHO ARE STUDENTS TRAINING TO BE PROFESSIONALS DESCRIBED ABOVE. VOTING MEMBERS ARE ONCOLOGY MEDICAL PROFESSIONALS WHO HAVE BEEN AWARDED AND HOLD THE DEGREE OF DOCTOR OF MEDICINE, DOCTOR OF OSTEOPATHY, DOCTOR OF PHILOSOPHY, DOCTOR OF PHARMACY, DOCTOR OF MEDICAL SCIENCE, DOCTOR OF NURSING SCIENCE, DOCTOR OF NURSING PRACTICE, OR EQUIVALENT DOCTORAL-LEVEL DEGREE AS DETERMINED FROM TIME TO TIME BY ASCO AND THE ASSOCIATION. ONLY VOTING MEMBERS ARE ELIGIBLE TO VOTE OR SERVE ON THE BOARD OF DIRECTORS, ON THE NOMINATING COMMITTEE, OR AS ELECTED OFFICERS. |
| FORM 990, PART VI, SECTION A, LINE 7A | VOTING MEMBERS OF ASCO ELECT ALL VOTING MEMBERS OF THE ASCO BOARD OF DIRECTORS. |
| FORM 990, PART VI, SECTION A, LINE 7B | ASCO'S CERTIFICATE OF INCORPORATION MAY ONLY BE AMENDED UPON THE VOTE OF THE MEMBERS ENTITLED TO VOTE, AND THE BYLAWS MAY ONLY BE AMENDED, AND DISSOLUTION OF THE CORPORATION MAY ONLY BE APPROVED WITH THE APPROVAL OF BOTH THE BOARD OF DIRECTORS AND VOTING MEMBERS OF ASCO. |
| FORM 990, PART VI, SECTION B, LINE 11B | AN ELECTRONIC COPY OF THE FINAL FORM WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS, AND WAS REVIEWED BY THE EXECUTIVE VICE PRESIDENT & CHIEF FINANCIAL OFFICER; THE CHIEF EXECUTIVE OFFICER; AND THE EXECUTIVE VICE PRESIDENT & CHIEF OPERATING OFFICER & CHIEF LEGAL OFFICER PRIOR TO FILING. |
| FORM 990, PART VI, SECTION B, LINE 12C | ASCO MAINTAINS A NUMBER OF WRITTEN CONFLICTS OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL ASCO MEMBERS AND EMPLOYEES, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND CERTAIN FAMILY MEMBERS (E.G. SPOUSE, DEPENDENT CHILDREN). COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS, CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE ALSO REQUIRED TO DISCLOSE SERVICE AS AN OFFICER, DIRECTOR, OR TRUSTEE OF ANY OTHER PROFESSIONAL OR ADVOCACY ORGANIZATION RELATING TO SCIENCE OR HEALTH CARE. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE AND UPDATED ANNUALLY THEREAFTER AND WHEN ANY MATERIAL CHANGES OCCUR. ASCO'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, IF ASCO WERE TO CONTEMPLATE ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY INTERESTED PERSON (I.E. AN ASCO DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF AN ASCO COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERNATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. |
| FORM 990, PART VI, SECTION B, LINE 15 | COMPENSATION OF CHIEF EXECUTIVE OFFICER (CEO): THE DUTIES OF THE CEO OF ASCO INCLUDE SERVING AS: THE CEO OF ASCO, THE EXECUTIVE VICE CHAIR OF ASCO'S NON-PROFIT, 501(C)(3) TAX- EXEMPT RELATED ORGANIZATION, CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CC); THE CEO OF ASCO'S NON-PROFIT, 501(C)(6) TAX-EXEMPT RELATED ORGANIZATION, ASCO ASSOCIATION (D/B/A ASSOCIATION FOR CLINICAL ONCOLOGY)(ASSOCIATION), THE PRESIDENT OF QOPI CERTIFICATION PROGRAM, LLC; THE PRESIDENT OF ASCO LEASING LLC, AND THE CHAIR OF THE BOARD OF GOVERNORS OF CANCERLINQ LLC. ALL ORGANIZATIONS LISTED ARE RELATED ORGANIZATIONS OF ASCO. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE CEO AND ASCO ADDRESSES COMPENSATION OF THE CEO. THE COMPENSATION OF THE CEO WAS DETERMINED BY THE ASCO BOARD OF DIRECTORS, FOLLOWING THE REVIEW AND RECOMMENDATION OF THE BOARD COMPENSATION COMMITTEE. THE COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE CEO WAS REASONABLE. THE REVIEW, RECOMMENDATION, AND DETERMINATION OF THE CEO'S COMPENSATION BASED ON THE ABOVE-DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2021. THE COMPENSATION OF THE FOLLOWING POSITIONS WAS CONSIDERED AND APPROVED BY THE ASCO BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND AN INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR EACH OF THE POSITIONS WAS REASONABLE. - EXECUTIVE VICE PRESIDENT & CHIEF OPERATING OFFICER & CHIEF LEGAL OFFICER & ASCO SECRETARY (EVP & COO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & COO BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2021. THE EVP & COO'S COMPENSATION WAS ALSO REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, AS REQUIRED UNDER STATE LAW. - EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER (EVP & CFO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CFO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2021. - EXECUTIVE VICE PRESIDENT & CHIEF MEDICAL OFFICER (EVP & CMO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CMO BASED ON THE ABOVE-DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2021. - EXECUTIVE VICE PRESIDENT & CHIEF DIGITAL OFFICER (EVP & CDO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CDO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2021. - EXECUTIVE VICE PRESIDENT OF ASCO & CHIEF EXECUTIVE OFFICER OF THE CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (EVP & CC CEO): THE EVP & CC CEO IS AN EMPLOYEE OF ASCO. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CC CEO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2021. - EXECUTIVE VICE PRESIDENT OF ASCO & CHIEF EXECUTIVE OFFICER OF CANCERLINQ LLC (EVP & CLQ CEO): THE EVP & CLQ CEO IS AN EMPLOYEE OF ASCO. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CC CEO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2021. |
| FORM 990, PART VI, SECTION C, LINE 18 | ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. |
| FORM 990, PART VI, SECTION C, LINE 19 | ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. |
| FORM 990, PART IX, LINE 11G | OTHER PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 7,314,021. MANAGEMENT AND GENERAL EXPENSES 1,886,264. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 9,200,285. DATA CURATION: PROGRAM SERVICE EXPENSES 7,743,865. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 7,743,865. PUBLIC RELATIONS: PROGRAM SERVICE EXPENSES 750,795. MANAGEMENT AND GENERAL EXPENSES 228,122. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 978,917. TEMPORARY STAFF: PROGRAM SERVICE EXPENSES 601,862. MANAGEMENT AND GENERAL EXPENSES 124,702. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 726,564. |
| FORM 990, PART XI, LINE 9: | PRIOR PERIOD ADJUSTMENT 1,326,214. |
| Software ID: | |
| Software Version: |